CTC
MNTA

Central Trust Company’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Central Trust Company’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-180
Closed -$3K – 1392
2017
Q2 		$3K Buy
+180
New +$2.74K ﹤0.01% 1140
2017
Q1 		– Sell
-500
Closed -$8K – 1222
2016
Q4 		$8K Buy
+500
New +$6.6K ﹤0.01% 1033

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Central Trust Company's MNTA Position: Q3 2017 in Review

Central Trust Company sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2017, closing a stake of 180 shares — an estimated $3K sold.

Central Trust Company first reported a position in MNTA in Q4 2016 and held it in 2 quarters. The position peaked at $8K in Q4 2016. 158 funds tracked by Wall St. Rank hold MNTA as of Q3 2017.

  • Central Trust Company reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Central Trust Company sold 180 Momenta Pharmaceuticals, Inc. shares in Q3 2017, an estimated $3K.
  • Central Trust Company first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2016 and held it in 2 quarters.
  • Central Trust Company's Momenta Pharmaceuticals, Inc. position peaked at $8K in Q4 2016.
  • 158 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2017.

Based on Central Trust Company's 13F filing for Q3 2017, filed 17 Oct 2017.